HemaCare to Present at Phacilitate Cell & Gene Therapy World 2016

HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, today announced that Lou Juliano, Senior Vice President of Global Sales and Business Development, will present recent findings by HemaCare’s research group on the sustainability of freshly isolated leukopaks (apheresis-derived white blood cells) when cryopreserved and shipped around the world for use in cell therapy applications. The results described in this presentation are of key importance to cell therapy researchers, who depend on HemaCare as a source for highly pure, viable, and functional cells to develop their therapies. Additionally, HemaCare will host a roundtable discussion on the importance of donor selection and management when used for the development of allogeneic cell therapies. This discussion will be critical to cell therapy companies who look to develop allogeneic “off-the-shelf” therapies that can treat multiple patients with engineered, cost-effective cancer treatments.

Phacilitate’s Cell & Gene Therapy World, at the Hyatt Grand Hotel in Washington, D.C., is considered the largest gathering of cell and gene therapy experts in the world with over 750 in attendance. Cell & Gene Therapy Forums draw leaders from the pharma and biotech communities to share the latest innovations in cell therapy.

“We continue to rapidly expand our offering in the cell therapy space and have noticed growing interest from our clients as well as prospective partners looking for ways to mitigate the variability of working with human cells to achieve the best possible research outcomes,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We value our ability to exceed our customers’ expectations by supplying human cells with consistently high purity, viability, and functionality. Our expertise in GMP/GTP-compliant cell collection, handling and logistics has made HemaCare a valuable partner, assisting cell therapy developers with their research, process development, clinical trials, cold chain management, and commercialization needs.”

Date/Time: Tuesday, January 26, 2016, 10:20-11:20 a.m.
Title: Apheresis Collection Starting Material for Allogeneic Cell Therapies: The importance of donor selection and management

• Lou Juliano, Senior Vice President, Global Sales & Business Development, HemaCare Corporation
• George Eastwood, Vice President, Sales & Business Development, HemaCare Corporation

Date/Time: Wednesday, January 27, 2016, 12:20 p.m.
Title: Cryopreserved Leukopaks maintain Cell Viability and Functionality; A Solution for Cell Therapy Logistics, Part II

• Lou Juliano, Senior Vice President, Global Sales & Business Development, HemaCare Corporation

About HemaCare

Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, Processing and Cell Therapy, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. For more information please visit www.hemacare.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005124/en/